test alice New PHD Article Basic


Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN

Nancy M. Albert

Panelist
HF.CVS.120 Pecha Kucha Says You Are What You Eat: Nutrition and Heart Failure
Saturday, Nov. 11, 9:45 a.m. - 11:00 a.m., Room 105AB

Carissa Baker-Smith, MD, MPH, FAHA, FACC, FAAP

Carissa Baker-Smith, MD, MPH, FAHA, FACC, FAAP

Panelist
CM.CVS.407 Great Debates in Weight Management: GLP1-RA: For Who? For What? And How? A Life Course Perspective
Sat, Nov 11, 3:15pm - 4:30pm
Room 204A

Full-Width Video Gallery (with images)

Must start with 7, but the more we add, the slower the page loads. In mobile, a tap to see/read button takes user immediately to the link, before it's possible to read the link text.

Don't Miss These Attractions:

Flipcard Gallery

Content looks miniature in mobile view. (This was built for logos). 4 - across only, no more, no less.

Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN | Cleveland Clinic
Carissa Baker-Smith, MD, MPH, FAHA, FACC, FAAP
Carissa Baker-Smith, MD, MPH, FAHA, FACC, FAAP | Nemours Children's Health
LaPrincess C. Brewer, MD, MPH
LaPrincess C. Brewer, MD, MPH | Mayo Clinic
Junbo Ge, MD
Junbo Ge, MD | Fundan University. CS.ME.564 Paul Dudley White International Lecture and Session Presentation Title: Panvascular Disease-What We Have Done and What We Can Do?
Amit Khera, MD, MSc, FACC, FAHA, FASPC
Amit Khera, MD, MSc, FACC, FAHA, FASPC | UT Southwestern Medical Center | Chair, Scientific Sessions | American Heart Association
Joanna Chikwe, MD, FRCS, FAHA
Joanna Chikwe, MD, FRCS, FAHA | Cedars Sinai Medical Center | Vice-Chair, Scientific Sessions | American Heart Association
Joseph C. Wu, MD, PhD, FAHA
Joseph C. Wu, MD, PhD, FAHA | Stanford University School of Medicine | President, American Heart Association

Friday, Nov. 10 Activities
Time Activity
08:00 a.m. - 12:45 p.m. Early Career Sessions at the Philadelphia Convention Center
3:00 p.m. - 6:00 p.m. Registration Opens

Saturday Paragraph

Saturday, Nov. 11 Activities
Time Activity
08:00 a.m. - 12:45 p.m. Early Career Sessions at the Philadelphia Convention Center
3:00 p.m. - 6:00 p.m. Registration Opens
1:00 p.m. - 2:00 p.m. Test 1 test 2 test 3
3:00 p.m. - 4:00 p.m. Another thing goes here
4:00 p.m. - 5:00 p.m. Session whatever goes here
3:00 p.m. - 6:00 p.m. Registration Opens

A photo of feet in red sneakers topped by dress slacks.

#AHA23: Know Before You Go!

To get the best out of AHA's biggest conference of the year, take a few minutes to get ready for #AHA23:

  • Plan your visit: Take time to plan what sessions you want to see and save valuable time onsite! Use our AHA conferences app to keep your choices at your fingertips.
  • Getting to and around Philadelphia: See our transportation information for helpful links
  • Wear Red Day: Bring something red to wear on Sunday, Nov. 12
  • Wear Sneakers Day: Show your style in comfort on Monday, Nov. 13
  • Registration Counter Hours - located in the Pennsylvania Convention Center Grand Hall
    • Thursday, Nov. 9 — 1:00 p.m. to 6:00 p.m.
    • Friday Nov. 10 — 6:30 a.m. to 5:00 p.m.
    • Saturday, Nov. 11 — 6:30 a.m. to 6:30 p.m.
    • Sunday, Nov. 12 — 7:00 a.m. to 5:00 p.m.
    • Monday, Nov. 13 — 7:00 a.m. to 3:00 p.m.

A photo of feet in red sneakers topped by dress slacks.

#AHA23: Know Before You Go

To get the best out of AHA's biggest conference of the year, take a few minutes to get ready for #AHA23:

  • Plan your visit:  take time to plan your days in advance and you'll save valuable time. Our AHA Conferences App helps keep your choices front and center onsite.
  • Check our Programming page for helpful links or PDFs to print in advance
  • Getting to and around Philadelphia: Transportation information
  • Wear Red Day: Add a splash of red to your wardrobe on Sunday, Nov. 12
  • Wear Sneakers Day: Show your style in comfort on Monday, Nov. 13

Late-Breaking Science Submissions
June 26 – August 22, 2023 at 6:00 p.m. CDT (UTC -5)
Submission fee: $300

Late-Breaking BASIC Science Submission
June 26 – August 22, 2023 at 6:00 p.m. CDT (UTC -5)
Submission fee: Members $49 / NonMembers $99

Looking for recommendations on how to improve your abstract? We highly recommend you view these recommendations from AHA journals.

Late-Breaking Science Abstract Information

  • Submission dates: June 26 to August 22, 2023 at 6:00 p.m. CDT (UTC -5)

  • Submission fee: $300

Late-Breaking Science sessions are innovative and provide the latest breakthroughs in clinical science. These sessions provide notable exposure and recognition for studies likely to have a significant impact on clinical practice and/or to make significant advances in a scientific field. The American Heart Association is excited to receive your late-breaking science!

Submission:
Abstracts submitted via the Late-Breaking submission process are expected to contain, at a minimum, the study design. Information on the characteristics of the patients enrolled is desirable as well. If available, the major trial results should be summarized and will be maintained confidential. Each submission must include a $300 online payment. If accepted, the abstract may be modified in the fall for publication, since the trial data presented at Scientific Sessions will be published online in the Circulation journal supplement. Any questions or concerns can be sent to Johanna Vanarsdall.

We understand the flexibility needed for trial timelines. For trials closing close to the deadline, please reach out to Johanna Vanarsdall and she will forward your concerns to the Chair and Vice-Chair of the Committee on Scientific Sessions Program.

Abstracts:

Abstract Character Limitations:
Character Max Limit: 2500
Character Min Limit: 50
Table Count Penalty: 250 Characters
Graphic Count Penalty: 250 Characters

The abstract with the overall design and major results which you submitted for consideration may be edited online in preparation for publication in Circulation. Further information with a link to the abstract site will be sent to you from [email protected] when editing is available in mid-October. The final abstract provided to AHA will be published in Circulation.

  • Abstract Copyright Transfer Agreement is collected at time of abstract submission. If you select "Yes", your abstract will be published in the online Circulation supplement and the online Program Planner. If you select "No", your abstract will be EXCLUDED from publication in online Circulation supplement and the online Program Planner.

  • If you submitted an abstract to the Scientific Session 2023 general abstract submission (April – June) that has the same focus as the abstract submitted to the LBS program, it may only be accepted in one format on the Scientific Sessions 2023 program. If accepted in both the general abstract submission and the LBS submission, please let Johanna Vanarsdall and [email protected] know via email so that we can withdraw the abstract accepted in the general program.

If you submitted an abstract(s) with separate analysis apart from this trial/presentation, that is acceptable. An abstract submitted to the general abstract submission for consideration in the general program that includes information other than the primary data from the clinical trial may be considered for presentation in the regular program at Scientific Sessions on a case-by-case basis. Please notify Johanna Vanarsdall and [email protected] if another abstract based on the clinical trial was submitted via the regular abstract submission process.

Use of Automated Assistive Writing Technologies and Tools:

  • The use of automated assistive writing technologies and tools (commonly referred to as artificial intelligence or machine learning tools) is permitted provided that their use is documented, and authors assume responsibility for the content. As with human-generated content, authors are responsible for the accuracy, validity and originality of computer-generated content. Automated assistive writing technologies do not qualify for authorship as they are unable to provide approval or consent for submission.
  • If the use of these technologies has involved the research design, the tools should be documented in the Methods. For additional information, see the World Association of Medical Editor recommendations.
  • For your abstract submission, you will need to indicate the use of these tools.

Additional Late-Breaking Science Submission Requirements:

Information regarding your science will be collected during the submission process. Not all questions may be applicable to your research. Please fill out the required steps during submission to the best of your ability.

  • Are implications for health equity addressed in the study findings?
  • Is this study testing a treatment/intervention to improve health outcomes?
  • Is this a First in Human therapeutic trial?
  • Availability of final data
  • Company supporting the trial
  • Disclosure of Unlabeled/Investigational Use of Drug or Product
  • Acronym and Marketing Description (that does not mention trial results or outcomes)
  • Principal Investigator

AHA is committed to improving health by ensuring the diversity of populations in scientific research. This is in keeping with FDA guidance and standards set by scientific journals.

  • Does the study include representation from women, and historically underrepresented racial and ethnic populations?
  • Is your study group representative of the people who have the condition of interest?

Featured Science:

During Late-Breaking Science submission, you have the option to select if your abstract may be considered for a Featured Science abstract. This means if your abstract is not selected to be presented as a Late Breaking Science abstract at Sessions 2023, it may be considered for a Featured Science abstract, and can be slotted as an oral presentation. Embargo policy for Featured Science remains the same as Late-Breaking Science.

Note: Industry announcements required by the SEC (Security Exchange Commission) must be approved by AHA prior to release and any level of information released without approval will be considered an embargo break.

AHA/ACC/ESC Acceptance/Embargos: Abstracts related to a clinical trial submitted for consideration for presentation at the American Heart Association, American College of Cardiology and European Society of Cardiology cannot be presented at the other two meetings. After acceptance by one of the organizations, that organization’s specific embargo guidelines prevail. An embargo means that results from the trial cannot be presented or announced in any forum prior to presentation at the meeting to which it has been accepted. Violators will be banned from participating in the clinical trials for two full cycles or for two of each organization’s meetings (AHA, ACC or ESC).

AHA Embargo Policies:

Clinical trial results are prohibited from being released until the date and time of AHA designated embargo time. For late-breaking science and featured science the embargo time is the date and time of presentation at Scientific Sessions 2023. Clinical trial sponsors must comply with embargo guidelines established by the American Heart Association.

You are prohibited from sharing written embargoed information with anyone outside of the AHA with the exception of journal manuscript submission. Important Note: Industry announcements required by the SEC (Security Exchange Commission) must be approved by AHA prior to release and any level of information released without approval will be considered an embargo break. However, you may conduct one-on-one embargoed media interviews as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in the trial being withdrawn on site and barred from presentation. Failure to honor this embargo policy may also jeopardize future acceptance of clinical trials and presentations at Scientific Sessions. Therefore, it is essential to recognize that presentations at unofficial satellite meetings or unofficial press conferences before the scheduled AHA embargoed media briefings are not allowed. This embargo policy will be strictly enforced.

Submission Categories:

  • Late-Breaking Randomized Clinical Trial – A clinical trial must include some type of intervention.

  • Clinical Trial Update – Update on a previously presented clinical trial. (Secondary analysis from the last year)

  • High Impact Science from Clinical Registries or Observational Studies

  • Themes:

    • Antithrombotic
    • CAD/ACS
    • Cardiometabolic
    • Electrophysiology
    • Epidemiology/ Prevention
    • First in Human/ Drug Discovery
    • Health Equity
    • Health Services
    • Heart Failure
    • HTN
    • Imaging
    • Interventional
    • Lipids
    • ReSS
    • Stroke
    • Surgery
    • Vascular

    Late-Breaking BASIC Science Abstract Information

    • Submission dates: June 26 to August 22, 2023 at 6:00 p.m. CDT (UTC -5)

    • Submission fee: Member $49/Non-member $99

    Late-Breaking Basic Science abstracts are described as highly meritorious, high-impact science. These innovative abstracts will provide the latest breakthroughs in basic science, presenting cutting-edge, exciting and pivotal research results. Emphasis will be given to genuine innovation and fundamental, distinctive, novel research. Abstracts will be evaluated based on their impact and novelty.

    Overall Abstract Submission Requirements

    • All abstracts must be submitted (and if accepted, will be presented) in English having accurate grammar and spelling suitable for publication.
    • Statistical results (including descriptive and inferential statistics) are to be included.
    • Author must affirm the work submitted is original and all statements declared as facts are based on thorough examination and investigation for accurateness.
    • Authors should not "split" statistical data to create several abstracts from one study. If splitting is judged to have occurred, prior scores of related abstracts will be negatively influenced.
    • Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
    • Proofread abstracts carefully to avoid errors before the submission deadline. The abstract will be published exactly as it has been submitted.
    • Submission of an abstract constitutes a commitment by the author(s) to present if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts for American Heart Association meetings/conferences.
    • There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed. If multiple submissions are accepted, the presenting author must resolve schedule conflicts by arranging for a co-author to present.
    • All abstract withdrawal requests must be received in writing via email to [email protected] by October 20, 2023, to avoid publication.

    Use of Automated Assistive Writing Technologies and Tools

    • The use of automated assistive writing technologies and tools (commonly referred to as artificial intelligence or machine learning tools) is permitted provided that their use is documented, and authors assume responsibility for the content. As with human-generated content, authors are responsible for the accuracy, validity and originality of computer-generated content. Automated assistive writing technologies do not qualify for authorship as they are unable to provide approval or consent for submission.
    • If the use of these technologies has involved the research design, the tools should be documented in the Methods. For additional information, see the World Association of Medical Editor recommendations.
    • For your abstract submission, you will need to indicate the use of these tools.

    Abstract Title

    • An abstract must have a short, specific title (containing no abbreviations or inflammatory language) that indicates the nature of the investigation.
    • Avoid an abstract title that reveals the results of the study. Explicit titles denoting the findings should be used (not “Investigations of…,” “Studies of…,” etc.)

    Author Name(s)

    • The submitting author will be designated as the primary and presenting author unless otherwise specified. The presenting author must be listed on the abstract and can be listed anywhere in the author block.
    • Please review the author block carefully. Edits cannot be made after the August 22, 6:00 PM CDT/UTC-5 deadline. Once submission is complete, the author block will be published as submitted. Additions or deletions of author names are not permitted after the submission deadline.

    Abstract Text

    • It is recommended abstracts have the following identifiable sections:
      • Introduction/Background
      • Research Questions/Hypothesis
      • Goals/Aims
      • Methods/Approach
      • Results/Data (descriptive and inferential statistics)
      • Conclusion(s)
    • Looking for recommendations on how to improve your abstract? We highly recommend you view these recommendations from AHA journals.
    • Use generic drug names.
    • Avoid beginning sentences with numbers.
    • Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
    • Do not include references, credits or grant support.
    • Do not include the names or personal information of any patient participating in the study or trial.
    • Abstract Character Guidelines:
      • Abstracts are limited to 1,950 characters (about 300-350 words).
      • Spaces do not count as characters.
      • Counts towards Character Limit:
        • Text in the abstract body
        • Graphics - Addition of an image whether a figure or a table deducts 250 characters.
      • Does not count towards character limit:
        • Title of abstract
        • Names of authors
        • Spaces in the abstract body
        • Caption of graphic
    • Graphics Guidelines
      • All graphics (figures) and text-based graphics (tables) should be provided as 72-300 dpi, pre-sized .BMP, .GIF, .JPG or .PNG images only, with a maximum width of 440 pixels (no limit on length). Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB color mode.
      • All graphics will require a brief description of the image.
      • Please Note: If an abstract is accepted for publication, any images submitted with the abstract are placed after the abstract that will appear in the online-only supplement to Circulation, an American Heart Association journal.

    Abstract Revisions

    • After the August 22, 2023, 6:00 PM CDT/UTC-5 deadline, your abstract submission is considered final and cannot be edited.
      • Abstracts may not be revised in any way or resubmitted.
      • Additions or deletions of author names will not be permitted.
    • Proofread abstracts carefully to avoid errors before submission.

    Abstract Copyright Transfer Agreement

    • Abstract Copyright Transfer Agreement will be electronically signed during submission.
      • Your selection of “Yes” will grant permission to publish.
      • Your selection of “No” will prohibit publication of the abstract in all formats including the Circulation supplement, ePoster site, the mobile meeting guide app, abstracts on USB/download and the online program planner.

    Abstract Review

    • Abstracts successfully submitted by the August 22, 2023, 6:00 pm CDT/UTC -5 deadline are posted to a secured web site for blind review. Our intent is to be inclusive of quality science received without compromising scientific integrity. As such, a team of 8 to 10 experts, selected by the Committee for Scientific Sessions Programming, independently reviews abstracts in the category that best fits their expertise.
    • Abstracts submitted for consideration must convey an original idea, concept, or an improvement or revision of a previous idea. Abstracts are selected on the basis of the following:
      • Scientific merit - direction toward the development of a new or improved diagnostic procedure or idea.
      • Organization - well organized, easy to follow and understand.
      • Practicality - should be available, logical and feasible.
      • Presentation - should be clear, brief, show understanding of the subject matter.
      • Technical quality - the idea must stand up to scrutiny. Facts and data have scientific backing.

    Abstract Acceptance

    • Abstract acceptance/non-acceptance status will be available by mid-September. Please ensure the email provided for the presenting author is accurate as all correspondences will be sent via email, to the presenting author only.
    • All communications regarding your abstract will be sent from [email protected]. Please make sure to add this email address to your email contacts to ensure important program participant related information gets through your spam filters, etc.
    • All accepted abstracts will be scheduled either in an oral or poster presentation format. All presentations including question-and-answers will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
    • Guidelines for abstract presentation will be included in the acceptance communication.

    Abstract Journal Publication

    • Accepted abstracts having selected “Yes” to the Abstract Copyright Transfer Agreement will be published online in the Circulation journal supplement.

    Embargo Policy

    • Abstracts and presentations are embargoed for release at 5 a.m. ET, Monday, November 6, 2023, and are therefore prohibited from release until date and time of AHA designated embargo time. You will be contacted by AHA communications if you are selected to participate in an AHA news event.
    • Written embargoed information cannot be shared with anyone outside of the AHA with the exception of a journal manuscript where one-on-one embargoed media interviews can be conducted as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in this abstract being withdrawn and future abstracts also being barred from presentation. Complete AHA Embargo Policy

    Recording Policy

    • Unauthorized recording of the AHA Scientific Sessions, scientific conferences, and the AHA/ASA International Stroke Conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
    • The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.

    Registration

    Get Advance rates through May 9

    Hotel

    Marriott Boston Copley Place

    Childcare

    Book childcare by May 3

    The fine print

    Policies, restrictions and more

    2023 Speakers

    Hooman Allayee, PhD

    Hooman Allayee, PhD
    University of Southern California Keck School of Medicine
    Presenting in Plenary Session 1: Gene-Environment Interactions in Cardiovascular Disease

    Katerina Akassoglou, PhD

    Katerina Akassoglou, PhD
    University of California, San Francisco
    Presenting in Concurrent Session 3b: Blood Coagulation in Health & Disease

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, MSCAI, FESC

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, MSCAI, FESC
    Mount Sinai Heart, Icahn School of Medicine
    Presenting the Distinguished Lecture in Plenary Session 5: Invited Lecture Series

    Alan Daugherty, PhD, DSc, FAHA

    Alan Daugherty, PhD, DSC, FAHA
    University of Kentucky
    Presenting in Concurrent Session 3c: Translational Science in Vascular Disease: Updates from the AHA Strategically Focused Vascular Disease Research Network

    Frank M. Davis, MD

    Frank M. Davis, MD
    University of Michigan
    Presenting in Concurrent Session 1c: Translational Science in Vascular Disease: New Insights into Abdominal Aortic Aneurysm

    Yun Fang, PhD

    Yun Fang, PhD
    University of Chicago
    Presenting in Concurrent Session 3a: Therapeutic Targets in Atherosclerosis

    Edward Fisher, MD, MPH, PhD

    Edward Fisher, MD, MPH, PhD
    NYU Langone Health
    Presenting in Concurrent Session 2a: Apolipoproteins, Lipoproteins and Lipid Metabolism

    Robert Gerszten, MD, FACC, FAHA

    Robert Gerszten, MD, FACC, FAHA
    Beth Israel Deaconess Medical Center, Harvard Medical School, Broad Institute 
    Presenting in Plenary Session 3: Vascular Disease in the Post-Genomic Era

    In-Person Registration

    Are you joining us in Chicago? Save your seat now

    Virtual Registration

    For registrants attending virtually ONLY

    Group Registration

    For groups of more than 40

    Housing and Transportation

    Reserve your room early for the best selection